Predictors of baseline cancer-related cognitive impairment in cancer patients scheduled for a curative treatment

Lycke, Michelle and Pottel, Lies and Pottel, Hans and Ketelaars, Lore and Stellamans, Karin and Van Eygen, Koen and Vergauwe, Philippe and Werbrouck, Patrick and Goethals, Laurence and Schofield, Patricia and Boterberg, Tom and Debruyne, Philip R. (2017) Predictors of baseline cancer-related cognitive impairment in cancer patients scheduled for a curative treatment. Psycho-Oncology, 26 (5). pp. 632-639. ISSN 1099-1611

Full text not available from this repository.
Official URL: https://doi.org/10.1002/pon.4200

Abstract

Introduction: Recent research in the field of cancer‐related cognitive impairments (CRCI) has shown CRCI presentation prior to treatment initiation. Some have attributed these problems to worry and fatigue, whereas others have suggested an influence of age, IQ, and other psychosocial and medical factors. Methods: Patients (≥18 years) with a histologically confirmed diagnosis of a solid cancer or hematological malignancy, scheduled for a curative treatment, were evaluated with a baseline neuropsychological assessment including Patient‐Reported Outcome Measures (PROMs). PROMs entailed distress, anxiety and depression, fatigue, and cognitive complaints. The neuropsychological assessment comprised several cognitive domains such as premorbid IQ, attention, processing speed, flexibility, verbal and visual episodic memory, and verbal fluency. Results: Cross‐sectional data of 125 patients were collected. Patients had a mean age of 60.9 years (range: 30.0‐85.0) and comprised primarily females (65.6%). Patients presented with cancer of following sites: breast (44.0%), digestive (28.8%), urological (11.2%), gynecologic (8.0%), hematologic malignancy (4.8%), and lung (3.2%). Patients presented with a premorbid IQ of 105.3 (range: 79.0‐124.0). In 29.6% of patients, a CRCI was detected. Binary logistic regression analyses showed that a lower premorbid IQ (β = −.084, P < .01) and a higher level of fatigue (β = −.054, P < .05) predicted baseline CRCI. Premorbid IQ also predicted performance on individual cognitive domains. Some domains were also influenced by age, gender, having a breast cancer diagnosis, and an active treatment for hypertension. Conclusion: Premorbid IQ and fatigue are important predictors of baseline CRCI. Therefore, we advise researchers to implement a short IQ test when conducting clinical trials on CRCI.

Item Type: Journal Article
Keywords: baseline, cancer, cancer‐related cognitive impairment, chemobrain, cognition, oncology
Faculty: ARCHIVED Faculty of Health, Social Care & Education (until September 2018)
Depositing User: Lisa Blanshard
Date Deposited: 23 Aug 2019 14:24
Last Modified: 14 Nov 2019 16:00
URI: http://arro.anglia.ac.uk/id/eprint/704665

Actions (login required)

Edit Item Edit Item